Léo Mas1, Alexandre Perrier2, Florence Coulet2
1Sorbonne Université, AP-HP, service d'Hépato-Gastroentérologie et Oncologie digestive, Hôpital Universitaire Pitié-Salpêtrière, 75013 Paris, France.
Advanced cholangiocarcinoma (CCA) shows frequent gene fusions, particularly FGFR2. Targeted therapies like FGFR and NTRK inhibitors offer new treatment options for advanced CCA patients.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science: